A Phase 3 Randomized Double-Blind Study of Pembrolizumab versus Placebo in Combination with Adjuvant Chemotherapy with or without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Carcinoma After Surgery with Curative Intent (MK3475 B21/ENGOT-en11/GOG-3053) | NYU Langone Health

Go Back to All Clinical Trials

A Phase 3 Randomized Double-Blind Study of Pembrolizumab versus Placebo in Combination with Adjuvant Chemotherapy with or without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Carcinoma After Surgery with Curative Intent (MK3475 B21/ENGOT-en11/GOG-3053)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Endometrial Neoplasms
Age: Between 18 years - 100 years
Gender: Female

Other Inclusion Criteria:

1) Has a histologically confirmed new diagnosis of Endometrial Carcinoma or Carcinosarcoma (Mixed Mullerian Tumor). 2) Has undergone curative intent surgery that included hysterectomy and bilateral salpingo-oophorectomy.

You may not be eligible for this study if the following are true:

1) Has recurrent endometrial carcinoma or carcinosarcoma. 2) Has uterine mesenchymal tumor such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas.